Cargando…

Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review

BACKGROUND: Understanding molecular pathogenesis of head and neck squamous cell carcinomas (HNSCC) has considerably improved in the last decades. As a result, novel therapeutic strategies have evolved, amongst which are epidermal growth factor receptor (EGFR)-targeted therapies. With the exception o...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Kort, W. W. B., Spelier, S., Devriese, L. A., van Es, R. J. J., Willems, S. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956931/ https://www.ncbi.nlm.nih.gov/pubmed/33686517 http://dx.doi.org/10.1007/s40291-021-00518-6

Ejemplares similares

p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer
por: de Kort, W. W. B., et al.
Publicado: (2023)

Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas
por: García-Carracedo, Darío, et al.
Publicado: (2016)

Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas
por: Su, Yu-Chieh, et al.
Publicado: (2022)

Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
por: Bang, Jieun, et al.
Publicado: (2023)

PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications
por: Aguayo, Francisco, et al.
Publicado: (2023)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Prognostic value of the nodal yield in head and neck squamous cell carcinoma: A systematic review
por: de Kort, Willem W. B., et al.
Publicado: (2019)

Patient-Derived Head and Neck Cancer Organoids Recapitulate EGFR Expression Levels of Respective Tissues and Are Responsive to EGFR-Targeted Photodynamic Therapy
por: Driehuis, Else, et al.
Publicado: (2019)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma
por: Bernard, Monique, et al.
Publicado: (2020)

EGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell Line
por: Treda, Cezary, et al.
Publicado: (2016)

Effect of typhaneoside on ventricular remodeling and regulation of PI3K/Akt/mTOR pathway
por: Zhang, X., et al.
Publicado: (2019)

mTOR Signalling in Head and Neck Cancer: Heads Up
por: Tan, Fiona H., et al.
Publicado: (2019)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
por: Ratti, Stefano, et al.
Publicado: (2022)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
por: Alves, Carla L., et al.
Publicado: (2023)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
por: Tian, Ling-Yu, et al.
Publicado: (2023)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer
por: Coppock, Joseph D., et al.
Publicado: (2016)

Linc01014 regulates gefitinib resistance in oesophagus cancer via EGFR‐PI3K‐AKT‐mTOR signalling pathway
por: Fu, Xiao, et al.
Publicado: (2019)

PSMC4 promotes prostate carcinoma progression by regulating the CBX3–EGFR‐PI3K‐AKT‐mTOR pathway
por: Liu, Kaifeng, et al.
Publicado: (2023)

The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
por: Su, Hengchuan, et al.
Publicado: (2013)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis
por: Ge, Fengmei, et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
por: Li, Huayi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n17j10ko3lrqdceihmu0h99tak